Skip to content

CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

Study on the Correlation Between CXCL2/CXCL8 and the Degree of Intervertebral Disc Degeneration and Radiological Progress

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05976516
Enrollment
40
Registered
2023-08-04
Start date
2023-08-01
Completion date
2024-03-30
Last updated
2023-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytokine, Intervertebral Disc, Degenerative

Keywords

cytokine, chemokine, Intervertebral Disc Degeneration

Brief summary

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.

Interventions

DIAGNOSTIC_TESTCXCL2/CXCL8

Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Sponsors

Zhongda Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form.

Exclusion criteria

* Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.

Design outcomes

Primary

MeasureTime frameDescription
CXCL2/8 content1 monthCXCL2/CXCL8 content of nucleus pulposus

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026